Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma
Umberto Vitolo, Marek Trněný, David Belada, et al.
Journal of Clinical Oncology (2017) Vol. 35, Iss. 31, pp. 3529-3537
Closed Access | Times Cited: 364

Showing 1-25 of 364 citing articles:

Diffuse Large B-Cell Lymphoma
Laurie H. Sehn, Gilles Salles
New England Journal of Medicine (2021) Vol. 384, Iss. 9, pp. 842-858
Open Access | Times Cited: 691
Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Laurie H. Sehn, Alex F. Herrera, Christopher R. Flowers, et al.
Journal of Clinical Oncology (2019) Vol. 38, Iss. 2, pp. 155-165
Open Access | Times Cited: 633
Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma
Hervé Tilly, Franck Morschhauser, Laurie H. Sehn, et al.
New England Journal of Medicine (2021) Vol. 386, Iss. 4, pp. 351-363
Open Access | Times Cited: 517
Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non–Germinal Center B-Cell Diffuse Large B-Cell Lymphoma
Anas Younes, Laurie H. Sehn, Peter Johnson, et al.
Journal of Clinical Oncology (2019) Vol. 37, Iss. 15, pp. 1285-1295
Open Access | Times Cited: 494
Past, Present, and Future of Rituximab—The World’s First Oncology Monoclonal Antibody Therapy
Timothy M. Pierpont, Candice B. Limper, Kristy L. Richards
Frontiers in Oncology (2018) Vol. 8
Open Access | Times Cited: 319
The regulation and function of CD20: an “enigma” of B-cell biology and targeted therapy
Gabriela Mladonická Pavlasová, Marek Mráz
Haematologica (2020) Vol. 105, Iss. 6, pp. 1494-1506
Open Access | Times Cited: 296
Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial
Andrew Davies, Thomas Cummin, Sharon Barrans, et al.
The Lancet Oncology (2019) Vol. 20, Iss. 5, pp. 649-662
Open Access | Times Cited: 226
Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial
Viola Poeschel, Gerhard Held, Marita Ziepert, et al.
The Lancet (2019) Vol. 394, Iss. 10216, pp. 2271-2281
Open Access | Times Cited: 210
ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma
Grzegorz S. Nowakowski, Annalisa Chiappella, Randy D. Gascoyne, et al.
Journal of Clinical Oncology (2021) Vol. 39, Iss. 12, pp. 1317-1328
Open Access | Times Cited: 197
CD20-TCB with Obinutuzumab Pretreatment as Next-Generation Treatment of Hematologic Malignancies
Marina Bacac, Sara Colombetti, Sylvia Herter, et al.
Clinical Cancer Research (2018) Vol. 24, Iss. 19, pp. 4785-4797
Open Access | Times Cited: 185
Fc-Engineering for Modulated Effector Functions—Improving Antibodies for Cancer Treatment
Rena Liu, Robert J. Oldham, Emma Teal, et al.
Antibodies (2020) Vol. 9, Iss. 4, pp. 64-64
Open Access | Times Cited: 167
Harnessing natural killer cells for cancer immunotherapy: dispatching the first responders
Nicholas A. Maskalenko, Dmitry Zhigarev, Kerry S. Campbell
Nature Reviews Drug Discovery (2022) Vol. 21, Iss. 8, pp. 559-577
Open Access | Times Cited: 140
Treatment strategies for patients with diffuse large B-cell lymphoma
Stefano Poletto, Mattia Novo, Luca Paruzzo, et al.
Cancer Treatment Reviews (2022) Vol. 110, pp. 102443-102443
Closed Access | Times Cited: 88
Cancer therapy with antibodies
Suman Paul, Maximilian F. Konig, Drew M. Pardoll, et al.
Nature reviews. Cancer (2024) Vol. 24, Iss. 6, pp. 399-426
Closed Access | Times Cited: 55
Genetic subtype-guided immunochemotherapy in diffuse large B cell lymphoma: The randomized GUIDANCE-01 trial
Mu‐Chen Zhang, Shuang Tian, Di Fu, et al.
Cancer Cell (2023) Vol. 41, Iss. 10, pp. 1705-1716.e5
Open Access | Times Cited: 47
A tale of two antibodies: obinutuzumab versus rituximab
Ciara L. Freeman, Laurie H. Sehn
British Journal of Haematology (2018) Vol. 182, Iss. 1, pp. 29-45
Open Access | Times Cited: 156
18F-FDG PET Dissemination Features in Diffuse Large B-Cell Lymphoma Are Predictive of Outcome
Anne‐Ségolène Cottereau, Christophe Nioche, Anne-Sophie Dirand, et al.
Journal of Nuclear Medicine (2019) Vol. 61, Iss. 1, pp. 40-45
Open Access | Times Cited: 132
New agents and regimens for diffuse large B cell lymphoma
Liang Wang, Linrong Li, Ken H. Young
Journal of Hematology & Oncology (2020) Vol. 13, Iss. 1
Open Access | Times Cited: 125
Management of relapsed/refractory DLBCL
Clémentine Sarkozy, Laurie H. Sehn
Best Practice & Research Clinical Haematology (2018) Vol. 31, Iss. 3, pp. 209-216
Closed Access | Times Cited: 121
Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial
Andrew D. Zelenetz, Gilles Salles, Kylie D. Mason, et al.
Blood (2019) Vol. 133, Iss. 18, pp. 1964-1976
Open Access | Times Cited: 121
Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b–2 study
Hervé Tilly, Franck Morschhauser, Nancy L. Bartlett, et al.
The Lancet Oncology (2019) Vol. 20, Iss. 7, pp. 998-1010
Open Access | Times Cited: 121
A randomized, open-label, Phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-Cell lymphoma: final analysis of GOYA
Laurie H. Sehn, Maurizio Martelli, Marek Trněný, et al.
Journal of Hematology & Oncology (2020) Vol. 13, Iss. 1
Open Access | Times Cited: 120
A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma
Franck Morschhauser, Pierre Feugier, Ian W. Flinn, et al.
Blood (2020) Vol. 137, Iss. 5, pp. 600-609
Open Access | Times Cited: 119
Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy
Shigeru Kusumoto, Luca Arcaini, Xiaonan Hong, et al.
Blood (2018) Vol. 133, Iss. 2, pp. 137-146
Open Access | Times Cited: 116
Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical Trials
Matthew J. Maurer, Hervé Ghesquières, Brian K. Link, et al.
Journal of Clinical Oncology (2018) Vol. 36, Iss. 16, pp. 1603-1610
Open Access | Times Cited: 112
Page 1 - Next Page

Scroll to top